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Lineage specification is a critical issue in develop-
mental and regenerative biology. We hypothesized
that microRNAs (miRNAs) are important participants
in those processes and used the poorly understood
regulation ofmegakaryocyte-erythrocyteprogenitors
(MEPs) in hematopoiesis as a model system. We
report here that miR-150 modulates lineage fate in
MEPs. Using a novel methodology capable of profil-
ing miRNA expression in small numbers of primary
cells, we identifymiR-150 as preferentially expressed
in the megakaryocytic lineage. Through gain- and
loss-of-function experiments, we demonstrate that
miR-150 drives MEP differentiation toward megakar-
yocytes at the expense of erythroid cells in vitro and
in vivo. Moreover, we identify the transcription
factorMYB as a critical target of miR-150 in this regu-
lation. These experiments show that miR-150 regu-
lates MEP fate, and thus establish a role for miRNAs
in lineage specification of mammalian multipotent
cells.
INTRODUCTION
Lineage specification is critical in mammalian development and
in the maintenance of adult tissue. The generation of mature ef-
fector cells in any organ involves the progressive differentiation
of stem cells and multipotent progenitors into committed cells
of distinct lineages. In mammals, this developmental hierarchy
has been most extensively studied in the hematopoietic system,
where well-characterized cell surface markers allow the purifica-
tion of distinct cell populations. Lineage specification has been
thought to be largely regulated at the level of transcription, where
lineage-specific transcription factors drive specific cell fates (for
review, see Cantor and Orkin, 2002; Friedman, 2002; Ye andDGraf, 2007; Zhu and Emerson, 2002). For example, the transcrip-
tion factor C/EBPa specifies neutrophilic differentiation (Fried-
man, 2002), and GATA-3 drives Th2 lineage commitment of
CD4 T cells (Zheng and Flavell, 1997). However, differential tran-
scription of transcription factors does not appear to explain all of
hematopoietic cell fate decisions, leading to the possibility that
other mechanisms exist for establishing cell fate. As an example,
the process by which megakaryocyte-erythrocyte progenitors
(MEPs) commit to becoming either erythroid precursors, yielding
mature red blood cells, or megakaryocytes, yielding mature
platelets, is unknown. Despite much effort, lineage-specific tran-
scription factors responsible for guiding the fate of MEPs have
not yet been identified.
We hypothesized that the developmental fate of mammalian
multipotent cells might be guided at least in part by a different
mechanism of gene regulation, namely by microRNAs (miRNAs).
These 22 nt noncoding RNAs negatively regulate the expres-
sion of target proteins primarily by inhibiting translation of their
cognate mRNAs through sites in the 30UTR (for review, see Bar-
tel, 2004), and are functionally important in diverse cellular pro-
cesses (Ambros, 2004; Chen et al., 2004), including the differen-
tiation of committed cells (Fazi et al., 2005; Fontana et al., 2007;
Fukao et al., 2007; Xiao et al., 2007; Zhou et al., 2007). Our pre-
vious finding, that miRNA expression patterns encode develop-
mental history, supports a role of miRNAs in lineage specification
(Lu et al., 2005).
In this study, we used MEP differentiation as a model system
to test this hypothesis. Using a novel miRNA profiling technol-
ogy, we profiled miRNA expression in MEPs and erythroid and
megakaryocytic primary cells and identified miR-150 with prefer-
ential expression in the megakaryocytic lineage. Gain- and loss-
of-function experiments established that miR-150 regulates
MEP fate to reciprocally modulate megakaryocytic and erythroid
development, through antagonizing a broadly expressed and
developmentally important transcription factor MYB (also known
as c-myb). Our results elucidate an important mechanism for the
poorly understood regulation of MEP fate, and establish a role for
miRNAs in mammalian lineage specification.evelopmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc. 843
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Development of a Sensitive, Genome-Wide miRNA
Expression Profiling Technology
To study miRNAs in MEP development, we took an unbiased
approach to profile the expression of miRNAs in MEPs and ery-
throid and megakaryocytic primary cells. Unfortunately, the
small number of precursor cells obtainable from human donors
has precluded a thorough analysis of miRNA expression in he-
matopoiesis (and other systems) using conventional miRNA pro-
filing methods, which generally either require large amounts of
input RNA, or are not amenable to genome-wide, high-through-
put applications. To address this technical challenge, we devel-
oped a method in which mature miRNAs are captured in 96-well
plates using immobilized 50-amino-modified oligonucleotides
complementary to the mature miRNA sequence of the more
than 300 human miRNAs in miRBASE release 7.0 (Griffiths-
Jones et al., 2006). This plate-based capture obviates the need
for gel-purification of small RNAs, which, in addition to being la-
bor intensive, results in significant loss of input miRNAs. The
captured miRNAs were ligated successively with adaptors on
30 and 50 ends, reverse transcribed, and amplified via PCR
(Figure 1A). The biotinylated PCR products were then detected
by hybridization to fluorescent beads coupled to capture oligo-
nucleotides that are complementary to the mature miRNA se-
quence. The beads were then analyzed by flow cytometry, where
the color of the bead indicates the identity of the miRNA and the
phycoerythrin channel indicates the abundance of that particular
miRNA (Lu et al., 2005). In contrast to our previously reported
method that required 10 mg of input RNA (Lu et al., 2005), the
present method yields similarly informative results with as little
as 10 ng of total RNA (Figure S1, see the Supplemental Data
available with this article online), allowing us to profile miRNA
expression in rare cell populations.
The Differential Expression of miR-150 Supports a Role
in MEP Fate Specification
With a suitable miRNA profiling method in hand, we examined
the miRNA expression pattern in MEPs and early megakaryo-
cytic and erythroid populations obtained from FACS-sorted
human umbilical cord blood samples. Using well-established
surface markers, we purified six populations of cells, and refer
to them as MEP (CD34+CD38+IL-3RaCD45RA), MEGA1
(CD34+CD41+CD61+CD45), MEGA2 (CD34CD41+CD61+
CD45), ERY1 (CD34+CD71+GlyA), ERY2 (CD34CD71+
GlyA), and ERY3 (CD34CD71+GlyA+). These six populationsDthus capture the bifurcation of the megakaryocytic and erythroid
lineages with fine granularity (Figure 1C).
Profiling of 320 miRNAs was performed to identify those most
differentially expressed across the human megakaryocytic and
erythroid populations (Figure 1B and Table S4). For example,
miR-451 and miR-144 were highly expressed in CD71+GlyA+
erythrocytes, and miR-222 was downregulated during erythro-
poiesis as previously described (Felli et al., 2005; Zhan et al.,
2007; Figure 1B). Differential analysis unexpectedly identified
miR-150, previously thought to be lymphocyte specific (Zhou
et al., 2007), with the most divergent expression between early
megakaryocytic and erythroid cells, with expression >15-fold
higher in megakaryocytes (Figure 1C and Table S1). Quantitative
RT-PCR analysis in sorted umbilical cord blood cells confirmed
miR-150 as being highly expressed in megakaryocytes, weakly
expressed in erythrocytes, and moderately expressed in MEPs
(Figure 1D and Figure S2). Similarly, miR-150 was expressed
more highly in CD41+CD61+ megakaryocytes than in CD71+GlyA+
erythrocytes in human adult bone marrow (Figure 1E).
In addition to differential expression, miR-150 displays exqui-
site sequence conservation across organisms with functional
erythrocytic and thrombocytic systems, exhibiting identical se-
quence in the 50 seed region that mediates target recognition
(Figure S3). Together, these pieces of evidence support the hy-
pothesis that miR-150 regulates lineage specification in MEPs.
miR-150 Reciprocally Regulates Megakaryocyte
and Erythrocyte Development In Vitro and In Vivo
To assess a potential causal role of miR-150 in the specification
of megakaryocytes versus erythrocytes, we performed a series
of in vitro and in vivo experiments.
First, we used a bilineage primary cell culture system, in which
human CD34+ hematopoietic progenitor cells isolated from adult
human bone marrow, when cultured in the presence of thrombo-
poietin (TPO) and erythropoietin (EPO), differentiate along the
megakaryocytic and erythroid lineages in vitro (Figure 2A). This
system allowed us to quantitate the proportion of megakaryo-
cytic and erythroid cells derived from progenitors following per-
turbation of miR-150. We transduced CD34+ cells with a lentiviral
construct harboring miR-150, resulting in a physiological level of
miR-150 expression that is similar to that observed in primary
megakaryocytes (Figure S4). Megakaryocytes were then enu-
merated by flow cytometry measuring the CD41+GlyA popula-
tion. Compared with CD34+ cells transduced with a control
vector (shLuc, expressing a short hairpin RNA (shRNA) against
luciferase), the miR-150-expressing cells yielded an 8-foldFigure 1. miRNA Expression Profiling Identified miR-150 as Being Preferentially Expressed in Megakaryocytes
(A) Schematic of a sensitive and high-throughput miRNA labeling methodology for expression profiling. RT, reverse transcription; Bi, biotin; blue and green ar-
rows, primers.
(B) Multiple harvests of MEP (n = 8), MEGA1 (n = 4), MEGA2 (n = 6), ERY1 (n = 4), ERY2 (n = 3), and ERY3 (n = 2) populations were purified from human umbilical
cord blood cells (Experimental Procedures) and profiled for miRNA expression. A heatmap is shown for log2-transformed data, with red color indicating higher
expression, and blue, lower expression. Data reflect the median expression of miRNAs within corresponding populations. Arrows point to miRNAs mentioned in
the text.
(C) Median expression of miR-150 was plotted for each population, with the oval area proportional to the expression level.
(D) miR-150 expression was measured using quantitative RT-PCR on multiple harvests of MEP (n = 3), MEGA1 (n = 4), MEGA2 (n = 3), ERY1 (n = 3), ERY2 (n = 3),
and ERY3 (n = 3) populations. The DCt values (Ct [threshold cycle] of 18S minus Ct of miR-150) are shown for all samples. Note that DCt reflects log scale of
expression. Samples indicated with black dots were also used in miRNA profiling in (B) and (C), whereas those with red circles are additional samples.
(E) Megakaryocytes (CD41+CD61+) and erythrocytes (CD71+GlyA+) were FACS-sorted from the bone marrow of a healthy adult human donor. miR-150 expres-
sion was measured using quantitative RT-PCR. Data reflect 2DCt in arbitrary units (AU). Error bars represent standard deviation.evelopmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc. 845
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(A) The function of miR-150 was assayed in an in vitro primary culture. CD34+ hematopoietic progenitors derived from human adult bone marrow cells were trans-
duced with viral constructs expressing a control hairpin (shLuc), miR-150, a mutant miR-150, or miR-15b-16-2. The cells were cultured in the presence of eryth-
ropoietin (EPO) and thrombopoietin (TPO) to differentiate toward erythrocytes and megakaryocytes, respectively, and were analyzed after 10 days of differen-
tiation using flow cytometry with lineage markers CD41 (megakaryocytic) and GlyA (erythroid).
(B) The effect of the expression constructs on the percentage of megakaryocytes (CD41+GlyA) is shown. The data reflect a representative triplicate experiment.
Error bars represent standard deviation. *p < 0.03.
(C) Representative flow cytometry plots are shown.enrichment (on average) of megakaryocytes (Figures 2B and 2C).
In contrast, mutant miR-150, or an irrelevant miRNA construct
(miR-15b-16-2), did not produce a significant increase in
megakaryocytes. This result indicates that miR-150 shifts the
balance of megakaryocytic-erythroid differentiation toward
megakaryocytes, and further suggests its role in governing the
fate of MEPs.
Having established a functionally important role of miR-150 in
a human in vitro model of MEP differentiation, we next examined
the function of miR-150 in vivo. To this end, we used a murine
bone marrow transplant model, in which stem/progenitor-cell-
enriched bone marrow cells from donor mice were transduced
with either miR-150 retrovirus or control virus, and then trans-
planted into lethally irradiated syngeneic recipient mice (Fig-
ure 3A). Both viral vectors carry GFP as a marker, allowing us
to distinguish between donor-derived cells that were transduced
from those that were not. To avoid early lethality of transplant
recipients due to possible impact on the erythroid lineage, and
to avoid a potential secondary compensatory mechanism, we
used low viral titer that resulted in20% transduction efficiency.846 Developmental Cell 14, 843–853, June 2008 ª2008 Elsevier IncUsing flow cytometry, we assayed the bone marrow cells with
megakaryocyte- and erythrocyte-specific markers (CD41 and
Ter119, respectively). Strikingly, compared to either nontrans-
duced (GFP) cells in miR-150 recipients, or vector control recip-
ient mice, miR-150 transduced (GFP+) bone marrow cells
exhibited a dramatic (>15-fold on average) expansion of mega-
karyocytes (CD41+Ter119) in relation to all transduced cells in
the bone marrow (Figures 3B and 3D and Table S5). In addition,
we observed a strong elevation in the expression of the mega-
karyocyte-specific gene PF4 (Ravid et al., 1991) in miR-150
transduced bone marrow cells (Figure 3E), and observed a con-
sistent 2- to 14-fold enrichment in GFP+ circulating platelets in
miR-150 animals compared with control (Figure 3F and Fig-
ure S6). These results proved that miR-150 expression led to
an increase in bone marrow megakaryocytes that were compe-
tent to produce mature platelets in circulation.
In contrast, forced expression of miR-150 led to a >60% de-
crease in GFP+ erythrocytes (Ter119+CD41), coupled with an
increase in GFP+ megakaryocytes in the bone marrow, in terms
of both percentage and cell number (Figures 3C and 3D and.
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miR-150 Regulates Lineage Specification in MEPsFigure 3. miR-150 Reciprocally Regulates Megakaryocyte and Erythrocyte Development In Vivo
(A) The function of miR-150 was assayed in a murine transplant model. Stem/progenitor-cell-enriched bone marrow cells from donor mice were transduced with
a control vector or a miR-150 expression construct. The vectors carry a GFP marker, thus labeling transduced cells and cells derived from them with green
fluorescence. The mixture of transduced and nontransduced donor cells was transplanted into lethally irradiated recipients. Bone marrow and peripheral blood
of recipients were analyzed 5 to 8 weeks posttransplantation, when the hematopoietic system had largely recovered in the hosts.
(B) The percentage of recipient bone marrow GFP+ or GFP megakaryocytes (CD41+Ter119) is shown. Each dot represents data from one recipient mouse.
n = 7.
(C) Bone marrow GFP+ or GFP erythrocyte (CD41Ter119+) percentage is shown. n = 7.
(D) Representative flow cytometry plots on bone marrow cells with megakaryocytic (CD41) and erythroid (Ter119) markers.
(E) Recipient bone marrow cells were FACS-sorted into GFP+ and GFP populations and measured for PF4 expression using quantitative RT-PCR. Each pair of
bars represents data from one recipient mouse.
(F) The circulating platelets were analyzed in the peripheral blood of recipient animals. The ratio of GFP+ platelet percentage to the percentage of GFP+ bone
marrow cells was plotted to reflect the thrombocytogenic potential of transduced bone marrow cells. n = 5.
(G) Representative flow cytometry plots of bone marrow cells assayed with CD71 and Ter119. The gates R1 to R4 represent immature to mature erythrocytes.
(H) The percentage of R1 population among all erythrocytes (sum of R1 to R4) was used to derive a ratio between GFP+ and GFP population within the same
recipient mouse. n = 7. p < 0.002.
(I) Data for R4 population, similarly derived as in (H). p < 23104.Figure S7). We further examined bone marrow cells with CD71
and Ter119, which distinguish different stages of murine ery-
throid differentiation (Socolovsky et al., 2001). The R1 to R4
gates on CD71/Ter119 plot show that miR-150-expressing cells
displayed a strong shift toward an immature state, compared
with controls (Figures 3G–3I). Specifically, miR-150 expression
led to an 8-fold increase on average in the immature R1 popula-Dtion, and a more than 60% decrease in the late R4 stage. These
experiments indicate that ectopic miR-150 expression induces
a block in the earliest definable stage of murine adult erythropoi-
esis, and causes a significant reduction in the total erythroid
population as well.
These in vitro and in vivo experiments showed that miR-
150 reciprocally regulates megakaryocytic and erythroidevelopmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc. 847
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in MEPs
(A) Bone marrow cells from vector control or
miR-150 recipient animals were sorted into GFP+
and GFP populations. Megakaryocyte colony-
forming units (CFU-Mks) were quantitated from
100,000 sorted cells. n = 4.
(B) Bone marrow cells from 5FU treated mice were
transduced with a control vector or miR-150, and
30,000 transduced bone marrow cells were
assayed for erythroid colony-forming units
(CFU-E).
(C) MEP cells sorted from wild-type C57Bl6/J mice
were assayed for CFU-Mk in the presence of PBS
(vehicle), antagomir against miR-150 (anti-150), or
a scrambled antagomir. Four thousand cells were
analyzed per assay. n = 4.
(D) LinKit+Sca+ (LKS) stem cells were assayed as
in (B). One thousand cells were analyzed per as-
say. n = 4.
(E) The expression of miR-150 in murine bone mar-
row cells was measured with quantitative RT-PCR
after 3 days of treatment with PBS or antagomirs.
Data reflect 2DCt in arbitrary units (AU). Error bars
represent standard deviation.
(F) Representative erythroid colonies from control-
vector-transduced or miR-150-transduced bone
marrow cells. Note that rare erythroid colonies
formed from miR-150 transduced cells showed
reduced cell number.
(G) A representative megakaryocyte colony grown
in the presence of antagomir-150 is shown. Brown
color reflects megakaryocyte-specific acetylcho-
linesterase activity.
(H) Mice were treated with PBS (control) or with
phenylhydrazine to induce anemia. miR-150 ex-
pression was assayed by quantitative RT-PCR in
lineage-negative cells purified from bone marrow.
n = 3. p < 0.001. Error bars represent standard
deviation.development, further supporting a role for miR-150 in lineage
specification of MEPs.
miR-150 Regulates Lineage Fate in MEPs
We next asked whether the megakaryocyte-promoting effect of
miR-150 was due to its effect on MEP commitment, or was sim-
ply an effect on the proliferation or survival of committed mega-
karyocytes. To address this, we used a colony formation assay
to quantitate the megakaryocytic potential of progenitor cells at
the single-cell level. We found that forced expression of miR-
150 resulted in a statistically significant increase in megakaryo-
cyte colony-forming units (CFU-Mk) in transduced bone marrow
cells (Figure 4A), coupled with a dramatic decrease in erythroid
colony formation (Figures 4B and 4F). These gain-of-function ex-
periments strongly suggest that miR-150 regulates MEP fate,
and not simply postcommitment megakaryocyte expansion.
To complement these miR-150 forced expression studies, we
turned to a loss-of-function approach. MEP cells were purified
from bone marrow and assayed for megakaryocyte colony forma-
tion in the presence or absence of an antagomir (a cholesterol-848 Developmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc.modified antisense oligonucleotide; Krutzfeldt et al., 2005) di-
rectedagainstmiR-150. Antagomir-150,butnot a scrambledcon-
trol, successfully knocked down miR-150 expression (Figure 4E).
MEPs treated with antagomir-150 showed more than a 4-fold de-
crease in CFU-Mk, compared with vehicle or a scrambled antago-
mir (Figure 4C). A similar effect was observed using purified un-
committed LinKit+Sca+ hematopoietic stem cells (Figure 4D).
Interestingly, miR-150 knockdown megakaryocyte colonies
showed normal morphology and acetylcholinesterase activity
(Figure 4G), suggesting that miR-150 is dispensable once MEP
commitment to the megakaryocyte lineage is established.
Having established a role of miR-150 in regulating MEP fate,
we reasoned that miR-150 expression may be regulated in pro-
genitor cells under physiologic challenge. We treated mice with
the anemia-inducing drug phenylhydrazine, and then measured
miR-150 expression in lineage-negative bone marrow cells,
which preceded evidence of erythroid differentiation. miR-150
expression was significantly decreased in this setting of in-
creased demand for erythropoiesis (Figure 4H). These data are
consistent with miR-150’s role in promoting megakaryopoiesis
Developmental Cell
miR-150 Regulates Lineage Specification in MEPsat the expense of erythropoiesis, and its alteration under a
physiologic challenge, such as anemia.
MYB Is a Functional Target of miR-150
The experiments described above firmly establish an important
role of miR-150 in the specification of megakaryocytes from
MEPs. We next sought to determine the mRNA targets of
miR-150 that explain its effect on megakaryocytic/erythroid out-
come. We started with the targets predicted in common among
several sequence-based prediction algorithms (Krek et al., 2005;
Lewis et al., 2005; Xie et al., 2005). We focused further onMYB as
a candidate because several recently reported mouse models, in
which MYB activity was reduced due to either mutation or the
serendipitous integration of a transgene near theMYB locus, dis-
played thrombocytosis and anemia (Emambokus et al., 2003;
Kasper et al., 2002; Mucenski et al., 1991; Mukai et al., 2006;
Sandberg et al., 2005). The expression of MYB messenger
RNA, however, is not immediately suggestive of a role in MEP
differentiation, because we observed similar expression in
MEPs and early erythroid and megakaryocyte populations
(Figure S8). Examination of the human MYB 30UTR, however,
identified multiple conserved miR-150 putative binding sites
(Figure S9).
To establish miR-150 as a functional negative regulator of
MYB, we first studied the human erythroblastic cell line K562
and the murine hematopoietic progenitor cell line EML-1, both
of which have the potential to be induced to differentiate into
erythroid or megakaryocytic cells. We observed a dramatic
reduction in MYB protein level upon ectopic expression of
miR-150 (Figure 5A and Figure S10). Next, we cloned the MYB
30UTR into a luciferase reporter and found that miR-150 re-
pressed reporter activity by more than 6-fold, again consistent
with miR-150 targeting MYB. Importantly, mutation of the four
candidate miR-150 binding sites abrogated miR-150 repression,
and a mutant miR-150 construct designed to be complementary
to the mutant MYB 30UTR binding sites restored miR-150-medi-
ated repression, but did not affect the wild-type MYB 30UTR
(Figures 5B and 5C). These experiments establish that
miR-150 negatively regulates the protein level of MYB directly
through its 30UTR.
Lastly, we addressed whether miR-150 repression of MYB ex-
plains miR-150’s erythroid/megakaryocytic effects. We tested
this hypothesis using the in vitro CD34+ human bone marrow
cell culture. Consistent with reports that mice with reduced
MYB activity develop megakaryocytosis (Emambokus et al.,
2003; Kasper et al., 2002; Mucenski et al., 1991; Mukai et al.,
2006; Sandberg et al., 2005), two independent shRNA con-
structs that knocked down MYB expression promoted megakar-
yocyte development (Figures 5D and 5E). In contrast, forced
expression of a MYB cDNA construct lacking its 30UTR resulted
in a decrease in megakaryocytes (Figures 4F and 4G). Moreover,
the MYB expression construct rescued the megakaryocyte-pro-
moting effect of miR-150, indicating that MYB is a functionally
relevant downstream effector of miR-150 (Figures 4F and 4G).
DISCUSSION
The work here demonstrates that miRNAs play an important role
in the developmental fate regulation of multipotent progenitorDcells in mammals. Our results challenge the view that miRNAs
merely play fine-tuning roles in establishing lineage fate (Bartel,
2004; Li et al., 2006). The function of miR-150 demonstrated
here provides some of the first insights into the regulation of
MEP fate decision, about which very little is known. Our studies,
of course, do not exclude the possibility that additional factors
may also contribute to the establishment of MEP fate.
Future investigations may use miR-150 as a tool to dissect the
details of extracellular and intracellular pathways that are in-
volved in MEP lineage specification. Furthermore, exploring the
regulation of miR-150 expression is also likely to be fruitful.
Both transcriptional and posttranscriptional mechanisms exist
for modulating miRNA expression (Chang et al., 2008; Thomson
et al., 2006). Thus, mapping the transcriptional start site of
miR-150, understanding its promoter elements, and investigat-
ing possible posttranscriptional control would shed light on the
regulation of miR-150 expression. We explored the possibility
that a feedback loop of MYB regulating miR-150 expression
might be utilized, but we saw no evidence of this in either
SupT11 or K562 cells (data not shown).
Identifying MYB as a functional target of miR-150 is consistent
with a recent study showing that MEPs with reduced MYB activ-
ity favor megakaryocytic as opposed to erythroid differentiation
(Mukai et al., 2006). In contrast to total loss of MYB function,
which results in complete hematopoietic failure (Mucenski
et al., 1991), our data indicate that modest modulation of MYB
expression levels by miR-150 can have important effects on lin-
eage specification. These results are particularly interesting in
light of the recent report of miR-150 regulation of MYB activity
in B lineage lymphocytes (Xiao et al., 2007). It has been generally
assumed that miRNAs have a plethora of targets that vary de-
pending on cellular context. Remarkably, MYB appears to be a
critical target of miR-150 both in establishing MEP fate and in
regulating the differentiation of lineage-committed B cells. This
observation suggests that a single mRNA target of a miRNA
might explain much of the miRNA’s function, even in completely
different developmental contexts. Our results, however, do not
exclude the possibility that other miR-150 targets may be in-
volved in establishing or maintaining MEP fate decision. For
example, pim-1, a predicated target of miR-150, is known to
positively regulate MYB (Leverson et al., 1998), suggesting that
miR-150 may suppress multiple genes in the MYB pathway. In
addition, miR-150 is predicated to target several genes associ-
ated with epigenetic regulation, which could play a role in lineage
specification. Further experiments are clearly needed to test
these hypotheses.
The miR-150/MYB mechanism may explain in part why
a search for lineage-specific expression of transcription factors
or other regulators has failed to identify key modulators of MEP
differentiation. Indeed, miR-150 is not megakaryocyte specific;
it is also abundantly expressed in lymphoid cells (Xiao et al.,
2007; Zhou et al., 2007). Similarly,MYB expression is not specific
to the erythroid and megakaryocytic lineages, but rather, it is
broadly expressed in hematopoiesis and beyond (Ramsay
et al., 2003). This observation suggests a mechanism by which
an exquisitely lineage-specific developmental program can be
executed through the combinatorial expression of a miRNA
and a transcription factor at the critical junction of lineage fate
specification. Given the large number of fate decisions requiredevelopmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc. 849
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transcription factor mechanisms are utilized in other develop-
mental settings. It is also conceivable that manipulation of
specific miRNAs to influence stem and progenitor cell fate might
have therapeutic value.
EXPERIMENTAL PROCEDURES
miRNA Expression Profiling and Data Analysis
miRNA expression profiling was performed using the plate capture method un-
less otherwise stated. 96-well PCR plates with N-oxysuccinimide surface
(DNA-BIND plates, Corning Costar) were coated at room temperature for
1 hr with 5 mM mixture of 50 amino-antisense oligonucleotides (see Table S2)
at 20 ml per well according to the manufacturer’s protocol. Coated plates
were successively washed with 100 mM Tris-HCl (pH 8.0), 150 mM NaCl,
and 1 mM EDTA; and 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA. Total RNA
(10 ng or higher) was diluted to 20 ml in 50 mM Tris-HCl (pH 8.0), 1 M NaCl,
1 mM EDTA, and 13 RNasecure (Ambion), containing precontrol synthetic
miRNA mixture at the ratio previously described (Lu et al., 2005). miRNAs
were captured in the coated wells by denaturing them at 80C for 5 min and
gradually cooling them to room temperature for 1.5 hr in a PCR machine, fol-
lowed by three 23SSC washes. 30 adaptor ligation and 50 adaptor ligations
were carried out as described (Lu et al., 2005) in 20 ml reaction volumes,
with four 23SSC washes after each ligation. Ligated miRNA were denatured
for 5 min at 80C in 20 ml water with 2 mM adaptor-specific RT primer, chilled
on ice, and reverse transcribed as described (Lu et al., 2005). RT products
were denatured at 95C for 5 min before two rounds of PCR amplification
with described conditions (Lu et al., 2005) for 26 and 27 cycles to incorporate
biotin labels for low-input RNA profiling. Labeled miRNAs were hybridized to
a bead-based detection platform (Lu et al., 2005) with updated detection
probes (Table S3). Median fluorescence intensities were quantitated on a
Luminex 100S machine (Luminex Corp).
Data were normalized as described (Lu et al., 2005) with modifications. Av-
erage readings from five water-only labeled samples were used for probe-spe-
cific background subtraction. Linear normalization among different bead sets
for the same sample was performed using readings from two postcontrol
probes with equal contribution. Sample normalization was subsequently
carried out assuming equal total fluorescence readings. To identify markers,
all ERY samples were compared to all MEGA samples, with median-based t
test and 50,000 permutations, using the ComparativeMarkerSelection module
in GenePattern (Reich et al., 2006).
Cell Sorting and Flow Cytometry
Human umbilical cord blood was harvested at Brigham and Women’s Hospital
with informed patient consent under an IRB approved protocol. Adult human
bone marrow cells were obtained from AllCells, LLC. Mononuclear cells were
purified by Ficoll Hypaque sedimentation. Lineage depletion was performed
using antibodies against CD2, CD3, CD4, CD5, CD8, CD11b, CD14C, CD19,
and CD56 with a magnetic column (Miltenyi Biotec). Populations were defined
as follows: MEP (CD34+CD38+IL-3RaCD45RA), ERY1 (CD34+CD71+GlyA),
ERY2 (CD34CD71+GlyA), and ERY3 (CD34CD71+GlyA+). Megakaryo-
cytes were purified without lineage depletion according to the following
immunophenotypes: MEGA1 (CD34+CD61+CD41+CD45) and MEGA2D(CD34CD61+CD41+CD45). Adult human bone marrow cells were similarly
sorted according to CD34CD61+CD41+ and CD34CD71+GlyA+. Sorting
was performed with a Vantage SE Diva or with an Aria (BD Biosciences).
RNA was extracted using TriZol (Invitrogen).
For the in vitro human primary culture experiment, approximately 500,000
cells were stained with CD41-FITC, Ter119-PE, and CD71-PE-Cy5 antibodies
for 15 min on ice and washed twice before flow cytometry. For analysis of
transplant recipients, murine bone marrow cells were labeled with CD41-PE
and Ter119-APC, or with Ter119-APC and CD71-PE. Peripheral blood cells
were harvested into 0.38% sodium citrate and stained with CD41-PE.
Mouse MEPs were purified as described in Akashi et al. (2000). Briefly, bone
marrow cells were harvested from 8- to 10-week-old C57Bl6/J mice and
stained with a lineage antibody cocktail containing biotinylated lineage
markers including Ter119, CD3, CD4, CD8, CD11b/Mac-1, Gr-1, and B220,
then stained with a second antibody cocktail containing streptavidin-PerCP,
Sca-PE, cKit-APC, CD16/32 PE-Cy7, and CD34-PacificBlue. MEPs are
defined as the LincKit+ScaCD34CD16/32 population.
Refer to the antibody section in the Supplemental Data for antibodies used.
Constructs
Constructs were prepared with standard molecular biology techniques. De-
tails of plasmids and their construction are available in the Supplemental Data.
Quantitative RT-PCR
Quantitative RT-PCR for miRNAs or mRNAs was performed using assays from
Applied Biosystems on an ABI HT7900 real-time PCR machine. Data were nor-
malized with 18S ribosomal RNA readings. DCt values (Ct of 18S minus Ct of
gene of interest) were used unless specified otherwise. Details are available in
the Supplemental Data.
In Vitro Primary Culture of Human CD34+ Cells
Cryopreserved human adult bone marrow CD34+ cells were obtained from
Cambrex (Poietics; Cambrex). Cells were cultured in Serum Free Expansion
Medium (SFEM, StemCell Technologies) supplemented with 100 U/ml penicil-
lin/streptomycin, 2 mM glutamine, and 40 mg/ml lipids (Sigma). Erythroid and
megakaryocytic differentiation were supported in a single liquid culture, simi-
larly to methodology described in Ebert et al. (2005), in the presence of
50 ng/ml TPO, 100 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6, and 0.5 U/ml
EPO. The concentration of EPO was increased to 3 IU/ml on day 7. Cells
were harvested for flow cytometry following 10 days of liquid culture. Lentiviral
infection was performed starting 1 day after thawing of cells. Where indicated,
cDNA construct and miRNA construct were infected on consecutive days.
Cells were selected with 2 mg/ml puromycin and/or 3 mg/ml blasticidin 1 day
after infection.
Murine Bone Marrow Transplant
All mice were purchased from the Jackson Laboratory. Murine bone marrow
transplant was performed similarly to previously described methods (Stier
et al., 2002), and approved by the MGH Subcommittee on Research Animal
Care. Donor C57Bl6/J mice (8 weeks) were primed with 150 mg/kg 5FU for
4 days. Bone marrow cells were purified by Ficoll (GE Healthcare) density gra-
dient centrifugation, following the manufacturer’s protocol. Cells were trans-
duced with empty vector or miR-150 retrovirus in X-VIVO 15 medium (Biowhit-
taker) supplemented with 100 ng/ml SCF, 50 ng/ml TPO, 50 ng/ml Flt3 ligand,Figure 5. MYB Is a Direct and Functional Target of miR-150
(A) K562 cells were transduced with constructs expressing GFP, mutant miR-150, or miR-150, and assayed for MYB and beta-tubulin with western blot analysis.
(B) Design of luciferase reporters for human MYB 30UTR, with green vertical bar indicating wild-type (wt) sites and red indicating mutant (mut) sites. The mutant
miRNA site and mutant 30UTR sites are complementary.
(C) Normalized luciferase activities in 293T cells. Error bars represent standard deviation. n = 8.
(D) CD34+ human adult bone marrow cells were transduced with control vector (shLuc), miR-150, or two independent shRNAs againstMYB in an in vitro culture as
described in Figure 2. The percentage of megakaryocytes (CD41+GlyA) was measured by flow cytometry. A representative triplicate experiment is shown.
(E) The knockdown of MYB by shRNAs was measured in K562 cells, as determined by quantitative RT-PCR. The values reflect 2DCt in arbitrary units (AU).
(F) miR-150 and MYB expression constructs and their corresponding vector controls (shLuc, Vector) were assayed in combination in the human CD34+ cell cul-
ture. A representative triplicate experiment is shown. *p = 0.04; **p < 0.01.
(G) Representative flow cytometry plots as described in (F).
Error bars in all panels represent standard deviation.evelopmental Cell 14, 843–853, June 2008 ª2008 Elsevier Inc. 851
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kara). To avoid possible early lethality of transplant recipients due to the neg-
ative effect of miR-150 on erythroid differentiation, and to avoid possible or-
ganismal compensatory effects, a low titer of virus was used, producing
20% transduction efficiency for both vector control and miR-150 constructs.
Lethally irradiated (9.5 Gy) recipient mice were transplanted with 2.5–4 million
cells the day after infection. Hematopoietic recovery was monitored by com-
plete blood count. Bone marrow cells of recipients were analyzed at 5–8 weeks
posttransplantation. Platelets were analyzed 7 weeks posttransplantation.
Cell Culture
K562 and 293T cells were obtained from ATCC and cultured according to
ATCC instructions. SupT11 was a kind gift from Dr. Gary Gilliland. EML-1 cells
were cultured in IMDM, supplemented with 20% horse serum and 20%
BHK/MKL-conditioned medium. Transfection was performed using FuGENE
6 (Roche). Retrovirus or lentivirus was produced in 293T cells following stan-
dard procedures.
Mouse bone marrow cells were treated with antagomir (50mg/ml) or PBS for
3 days in X-VIVO 15 medium (Biowhittaker) supplemented with 50 ng/ml SCF,
50 ng/ml TPO, 50 ng/ml Flt3 ligand, and 20 ng/ml IL-3. Cells were then
harvested for RNA analysis.
Oligonucleotides and Antagomirs
DNA oligonucleotides were synthesized by IDT Technology. RNA oligonucle-
otides, including antagomirs and DNA-RNA hybrids, were synthesized by
Dharmacon. Antagomir stock solution was prepared in PBS. Antagomir-150:
50 mC(*)mA(*)mCmUmGmGmUmAmCmAmAmGmGmGmUmUmGmGmG(*)
mA(*)mG(*)mA (*)(30-Chl) 30. Antagomir-scrambled: 50mC(*)mU(*)mCmGmCm
GmUmAmGmA mAmGmAmGmUmAmGmGmU(*)mG(*)mG(*)mA(*) (30-Chl)
30. (mN, 20OMe base; *, phosphorothioate linkage; Chl, cholesterol).
Colony Assay
Megakaryocyte colony assay was performed using the MegaCult-C kit
(StemCell Technologies) according to the manufacturer’s protocol. Bone mar-
row cells from recipient mice 7–10 weeks after transplantation were sorted into
GFP and GFP+ populations. Two recipient mice were analyzed for each con-
struct, and each population of cells was assayed in duplicates with 100,000
sorted bone marrow cells per well. Cultures were maintained for 8 days before
stained for acetylcholinesterase activity and scored. For antagomir treatment,
1000 LKS cells or 4000 MEPs were FACS-sorted and assayed in the presence
of antagomir (50 mg/ml) or PBS and maintained in culture for 11 days before
staining and scoring. In all cases, a colony withR3 acetylcholinesterase-posi-
tive cells was scored as a megakaryocyte colony.
For erythroid colony assay, 5FU primed wild-type C57Bl6/J marrow was
transduced as described above. Forty-eight hours after viral transduction,
thirty thousand GFP+ cells were FACS-sorted and plated into methylcellulose
(StemCell Technologies, M3334), which only contains EPO.
Anemic Response
Phenylhydrazine hydrochloride (Sigma) solution in PBS was injected intraper-
itoneally into 10- to 12-week-old wild-type C57Bl6/J mice (60 mg/kg body
weight) on day 0, 1, and 2. On the third day, mice were euthanized by CO2 in-
halation and bone marrow was harvested and stained with a lineage marker
antibody cocktail as described in the Cell Sorting and Flow Cytometry subsec-
tion. Lineage-negative cells were FACS-sorted into TriZol reagent for RNA
preparation.
Western Blot Analysis
Western blot analysis was performed as previously described (Lu et al., 2004).
Cells were infected with retroviral constructs and selected with puromycin for
2 days before harvesting.MYB antibody (clone 1-1) was from Upstate Biotech-
nology. Beta-tubulin antibody (ab6046) was from Abcam.
Luciferase Reporter Assay
293T cells were plated in 96-well plates at 5000 cells per well the day before
transfection. Transfection was carried out in eight replicates using FuGENE
6 (Roche), with 100 ng of plasmid mixture (90 ng of expression vector and
10 ng of reporter vector in the psiCHECK2 backbone). Luciferase assays852 Developmental Cell 14, 843–853, June 2008 ª2008 Elsevier Incfor both firefly and renilla luciferase were performed 2 days after transfection,
using the Dual-Glo Luciferase assay kit (Promega). Luminescence was quan-
titated on a Tecan Spectrafluor Plus machine. Renilla luciferase readings
were normalized against the firefly luciferase activity in the corresponding
well.
Statistical Analysis
Student’s t test (two-tailed, unequal variance) was used for statistical analysis
on experiments unless otherwise specified.
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